据港交所官网，山东信得科技股份有限公司（以下简称"信得科技"）日前首次向港交所呈交了IPO（首次公开募股）申请文件，工 银国际和中泰国际为联席保荐人。据招股书（申请版本，下同），信得科技拟将此次港股IPO募集资金用于研发计划及扩展产品组 合、扩大产能、拓展海外市场以及营运资金及其他一般公司用途。 《每日经济新闻》记者（以下简称"每经记者"）注意到，尽管信得科技称其在中国动物保健市场中排名靠前，但该行业面临激烈 的竞争，且客户在兽用生物制品及药物采购方面的议价能力提升，或影响其盈利能力。此外，信得科技在2024年因抗体产品的平 均售价下降导致收入和利润"双降"。值得一提的是，信得科技的估值在C轮融资过后达到约18亿元，但较B轮融资及于2022年8月进 行的股份转让后的约28.78亿元的估值缩水了近四成。 客户议价能力提升或降低公司盈利能力 信得科技成立于1999年，是中国一家动物保健企业，其主要从事全系列动物保健及配套产品的研发、生产及销售，产品涵盖兽用 生物制品（如疫苗、抗体、转移因子等）、中兽药、化药制剂、动物饲料及饲料添加剂，实现对家禽、家畜、水产动物及宠物疾 病的预防、诊断、治疗与控制。 招股书援引灼识 ...

动物保健行业头部企业，中国禽用兽用生物制品排名第三的供应商，2025年收入利润双增的信得科技赴港上市。 | | | 截至12月31日止年度 | | | | 截至9月30日止九個月 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | 2023年 | | 2024年 | | 2024年 | | 2025年 | | | 人民幣千元 | % - | 人民幣千元 | % | 人民幣千元 | 6 | 人民幣千元 | | 獸用生物製品 | | | | | | | | | 疫苗產品 | 464.952 | 47.2 | 476.267 | 48.5 | 346.917 | 49.5 | 471.332 | | 抗體產品 | 96,414 | 9.8 | 86,230 | 8.8 | 63,470 | 9.1 | 66,797 | | 轉移因子 | 64.948 | 6.6 | 68,033 | 6.9 | 47.317 | 6.8 | 67.282 | | 小計 | 626.314 | 63.6 | 630.530 | 64.2 | 457.704 | 65.4 ...

来源：智通财经 文 | 周涛 山东宠物经济或再壮大。 2026年2月16日，一家来自山东潍坊诸城的"隐形冠军"企业——山东信得科技股份有限公司，向香港联 合交易所递交了主板上市申请，为自己的资本市场之旅按下了启动键。 图片来源：港交所 根据灼识咨询的报告，以2024年收入计，信得科技在中国动物保健市场的国产厂商中排名第九，市场份 额约为1.4%。 然而，其真正的核心竞争力体现在更为细分的领域：在中国禽用兽用生物制品市场，公司稳居前三。 | 量纂]的[编纂]數目 : [編纂]股H股(視乎[編纂] | | | | --- | --- | --- | | 行使與否而定) | | | | [編纂]數目 | .. | [編纂]股H股(可予[編纂]) | | [編纂]數目 | . . | [編纂]股H股(可予[編纂]及視乎[編纂] | | 行使與否而定) | | | | 最高[編纂] | .. | 每股H股[編纂]港元,另加1.0%經紀 | | 佣金、0.0027%證監會交易徵費、 | | | | 0.00015%會財局交易徵費及0.00565% | | | | 香港聯交所交易費(須於[編纂]時以港 | | | | 元繳 ...

Core Viewpoint - Shandong Xinde Technology Co., Ltd. has submitted its prospectus to the Hong Kong Stock Exchange for a main board listing, with ICBC International and Zhongtai International as joint sponsors [1] Company Overview - Established in 1999 and located in Weifang, Shandong, Xinde Technology is a leading animal health enterprise in China, focusing on the R&D, production, and sales of a full range of animal health products [3] - The product matrix includes veterinary biological products (vaccines, antibodies, transfer factors), traditional Chinese veterinary medicine, chemical drug formulations, feed, and feed additives, catering to the health management needs of poultry, livestock, aquatic animals, and pets [3] - The company has been recognized as a national enterprise technology center, a high-tech enterprise, and a specialized and innovative small giant enterprise by the Ministry of Industry and Information Technology [3] Market Position - According to ZhiShi Consulting, Xinde Technology ranks 9th among domestic manufacturers in China's animal health market with a market share of approximately 1.4% as of 2024, and it is among the top three in the poultry veterinary biological products market [3] - The company holds the leading market share in specific segments such as veterinary transfer factors, Newcastle disease vaccines, and avian mycoplasma vaccines [3] Technological Innovation - Xinde Technology emphasizes technological innovation, holding 12 national-level new veterinary drug approvals, 25 biological product approvals, and 21 traditional Chinese veterinary medicine approvals [5] - It is one of the first companies globally to use suspension culture technology for producing highly pathogenic avian influenza vaccines and has launched the first quadrivalent poultry vaccine in China [5] Production Capacity - The company has established four production bases in Shandong and Beijing, equipped with 34 production lines certified by the new veterinary drug GMP standards, and has invested 1.1 billion yuan in advanced manufacturing capacity [5] Financial Performance - The unaudited financial data shows that Xinde Technology achieved revenues of 985 million yuan, 982 million yuan, and 877 million yuan for the years 2023, 2024, and the first nine months of 2025, respectively [5] - Gross profits for the same periods were 456 million yuan, 452 million yuan, and 436 million yuan, with gross margins of 49.7%, 50.8%, and 55.3% [5] - The net profits for these periods were 34.76 million yuan, 28.12 million yuan, and 55.67 million yuan, indicating a steady improvement [5] International Expansion - Xinde Technology's overseas revenues were 12.2 million yuan, 28.3 million yuan, and 46.1 million yuan for the same periods, showing rapid growth, with products entering markets in Pakistan, Egypt, and Vietnam [5] - The company is also working on distributor registrations in 31 countries [5] Shareholding and Management - As of February 7, the controlling shareholder is the company's chairman and president, Li Chaoyang, who holds 45.08% of the voting rights [6] - Sumitomo Corporation, a Fortune Global 500 company, is a strategic shareholder [6] Industry Environment - The Chinese animal health industry is currently experiencing a dual track of policy tightening and market expansion, with the implementation of new veterinary drug GMP certifications accelerating industry reshuffling [6] - The market size for China's animal health sector is projected to reach 68 billion yuan in 2024, with a compound annual growth rate (CAGR) of 6.0% from 2019 to 2024, and expected to grow to 141 billion yuan by 2034 [6] - The global animal health market is estimated to be approximately 51.1 billion USD in 2024, with projections of reaching 85.8 billion USD by 2034 [6] Fundraising Purpose - Although specific amounts are not disclosed, the funds raised from the IPO will primarily be used to expand production bases and capacity, enhance R&D in new vaccines, chemical drugs, and pet medicines, and expand domestic and international sales networks [6] - The company aims to deepen its integrated development model of "mineral + energy," consolidate its domestic market advantage, accelerate overseas market penetration, and seize opportunities in emerging sectors such as pet economy and antibiotic-free farming [6]

Group 1 - The core viewpoint of the article is that Shandong Xinde Technology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, aiming to expand its presence in the animal health market [1] - Shandong Xinde Technology was established in 1999 and is recognized as a leading animal health company in China [1] - The company engages in the research, production, and sales of a full range of animal health products, including veterinary biological products, traditional Chinese veterinary medicine, chemical preparations, animal feed, and feed additives [1] Group 2 - According to the prospectus, Shandong Xinde Technology ranks ninth among domestic manufacturers in the Chinese animal health market based on projected revenue for 2024 [1] - The company is also ranked among the top three in the Chinese veterinary biological products market for poultry [1]

Company Overview - Shandong Xinde Technology Co., Ltd. is a leading animal health enterprise in China, established in 1999, focusing on the research, production, and sales of a full range of animal health products [3] - The company ranks ninth among domestic manufacturers in the Chinese animal health market, with a market share of 1.4% as of 2024 [4][12] - Its product offerings include veterinary biological products, traditional Chinese veterinary medicine, chemical drug formulations, animal feed, and feed additives [3] Business Model - The company operates on two core drivers: providing precise prevention and control solutions and leveraging innovation and production capabilities to deliver high-quality, cost-effective products [3][5] - It has established four production bases and 34 production lines certified by the new veterinary drug GMP [4] Financial Performance - The company's revenue for the nine months ending September 30 for 2023, 2024, and 2025 was approximately RMB 985 million, RMB 982 million, and RMB 878 million, respectively [6] - The net profit for the same periods was RMB 34.76 million, RMB 28.12 million, and RMB 55.67 million, respectively [7] - The gross profit margin improved from 49.7% in 2023 to 55.3% in 2025 [8] Industry Overview - The global animal health market was valued at USD 40.2 billion in 2019 and is projected to grow to USD 51.1 billion by 2024, with a CAGR of 4.9% [11] - The Chinese animal health market is expected to grow from RMB 509 billion in 2019 to RMB 680 billion by 2024, with a CAGR of 6.0% [12] Market Drivers - The increasing difficulty in animal disease prevention and control due to globalization and cross-border logistics has heightened the demand for effective animal health solutions [16] - The trend towards large-scale farming is evident, with the proportion of large-scale pig farming in China expected to rise from 50% in 2019 to 70% by 2024 [16] - There is a growing demand for pet health care driven by the increasing number of single-person households and an aging population in China [17]

据港交所2月16日披露，山东信得科技股份有限公司(简称：信得科技)向港交所主板递交上市申请书， 工银国际、中泰国际为其联席保荐人。根据灼识咨询的资料，以2024年收入计，该公司是在中国动物保 健市场中排名第九的国产厂商，并在中国禽用兽用生物制品市场排名前三。 据招股书，成立于1999年，该公司是中国领先的动物保健企业。该公司主要从事全系列动物保健及配套 产品的研发、生产及销售，产品涵盖兽用生物制品(如疫苗、抗体、转移因子等)、中兽药、化药制剂、 动物饲料及饲料添加剂，实现对家禽、家畜、水产动物及宠物疾病的预防、诊断、治疗与控制。 ...

智通财经APP获悉，据港交所2月16日披露，山东信得科技股份有限公司(简称：信得科技)向港交所主板 递交上市申请书，工银国际、中泰国际为其联席保荐人。根据灼识咨询的资料，以2024年收入计，该公 司是在中国动物保健市场中排名第九的国产厂商，并在中国禽用兽用生物制品市场排名前三。 据招股书，成立于1999年，该公司是中国领先的动物保健企业。该公司主要从事全系列动物保健及配套 产品的研发、生产及销售，产品涵盖兽用生物制品(如疫苗、抗体、转移因子等)、中兽药、化药制剂、 动物饲料及饲料添加剂，实现对家禽、家畜、水产动物及宠物疾病的预防、诊断、治疗与控制。 ...

Core Insights - Chongqing aims to establish a digital trading platform centered around "Chinese Huanglian" and achieve an industrial chain output value exceeding 3 billion yuan [1][2] Group 1: Industry Development - Chongqing is a major production area for traditional Chinese medicine, with Huanglian cultivation covering nearly 100,000 acres, accounting for approximately 60% of national demand [1] - The city promotes standardized ecological planting of Huanglian, implementing integrated pest management and organic fertilizer use [1] - A comprehensive product system has been developed, utilizing all parts of Huanglian for various products, including traditional Chinese medicine, food, and daily chemical products [1] Group 2: Brand and Market Strategy - The "Shizhu Huanglian" regional public brand has been established, recognized as one of the top 100 public brands in traditional Chinese medicine [2] - A collaborative model involving leading enterprises, cooperatives, and farmers has been adopted, with 10 leading enterprises and 25 cooperatives developed [2] - The "China Huanglian Trading Market" in Shizhu has seen annual transaction volumes exceeding 1 billion yuan, establishing a new market development pattern [2] Group 3: Future Initiatives - A high-quality development conference for the Huanglian industry will be held on August 28-29, aiming to enhance the industry's national influence [2]

加快推进兽医学科"双一流"建设，中国农大动物医 学院成立临床兽医学部 近日，中国农业大学动物医学院发布了关于成立动物医学院临床兽医学部的通知。 她主要围绕人类健康、动物健康从事中兽药现代化和创新药物开发及中药材在畜牧业开发利用的研究工 作，研究领域包括中兽药现代化和创新药物开发、中药材在畜牧业开发利用的研究、中兽药药理与毒理 研究等，长期坚持科研来源于生产一线、成果聚焦解决产业实际问题的工作理念，多年来与行业一线企 业和养殖端保持着紧密稳定的合作关系。 中国农业大学动物医学院是中国农业大学历史最为悠久的学院之一，其兽医学学科最早可追溯至1902年 颁布的《钦定京师大学堂章程》中"农业科之目四，一曰农艺学、二曰农业化学、三曰林学、四曰兽医 学" 记载。自1905年京师大学堂农科肇始，1949年北大、清华及华北大学农学院合并成北京农业大学， 设立兽医系，1984年成立兽医学院，1993年更名为动物医学院。学院兽医学学科为教育部双一流建设 A+学科，拥有基础兽医学、预防兽医学、临床兽医学、兽医生物工程和兽医公共卫生5个二级学科。 中国农业大学动物医学院官网显示，夏兆飞分别于1991年、1997年硕士、博士毕业于中国 ...